rs1114167415
Variant summary
Our verdict is Pathogenic. The variant received 11 ACMG points: 11P and 0B. PM1PM2PM5PP2PP3_Strong
The NM_000089.4(COL1A2):c.3089G>A(p.Gly1030Asp) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 13/22 in silico tools predict a damaging outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. G1030A) has been classified as Pathogenic.
Frequency
Consequence
NM_000089.4 missense
Scores
Clinical Significance
Conservation
Publications
- Ehlers-Danlos syndrome, arthrochalasia type, 2Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Genomics England PanelApp, Illumina, PanelApp Australia, Labcorp Genetics (formerly Invitae)
- osteogenesis imperfectaInheritance: AD Classification: DEFINITIVE Submitted by: G2P
- osteogenesis imperfecta type 1Inheritance: AD Classification: DEFINITIVE, SUPPORTIVE Submitted by: Orphanet, ClinGen
- osteogenesis imperfecta type 2Inheritance: AD Classification: DEFINITIVE, SUPPORTIVE Submitted by: Orphanet, G2P, ClinGen
- osteogenesis imperfecta type 3Inheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Labcorp Genetics (formerly Invitae), Orphanet, ClinGen
- osteogenesis imperfecta type 4Inheritance: AD Classification: DEFINITIVE, SUPPORTIVE Submitted by: Orphanet, ClinGen
- Ehlers-Danlos syndrome, arthrochalasia typeInheritance: AR, AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Labcorp Genetics (formerly Invitae), Orphanet, ClinGen
- Ehlers-Danlos syndrome, cardiac valvular typeInheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Genomics England PanelApp, ClinGen, PanelApp Australia, Orphanet, G2P
- combined osteogenesis imperfecta and Ehlers-Danlos syndrome 2Inheritance: AD Classification: MODERATE Submitted by: ClinGen, Ambry Genetics
- Ehlers-Danlos/osteogenesis imperfecta syndromeInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- high bone mass osteogenesis imperfectaInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 11 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| COL1A2 | NM_000089.4 | c.3089G>A | p.Gly1030Asp | missense_variant | Exon 46 of 52 | ENST00000297268.11 | NP_000080.2 |
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| COL1A2 | ENST00000297268.11 | c.3089G>A | p.Gly1030Asp | missense_variant | Exon 46 of 52 | 1 | NM_000089.4 | ENSP00000297268.6 | ||
| COL1A2 | ENST00000478215.1 | n.648G>A | non_coding_transcript_exon_variant | Exon 4 of 4 | 3 | |||||
| COL1A2 | ENST00000481570.5 | n.3062G>A | non_coding_transcript_exon_variant | Exon 5 of 8 | 2 | |||||
| COL1A2 | ENST00000488121.1 | n.5G>A | non_coding_transcript_exon_variant | Exon 1 of 3 | 2 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD2 exomes AF: 0.00 AC: 0AN: 229906 AF XY: 0.00
GnomAD4 exome Cov.: 32
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Osteogenesis imperfecta with normal sclerae, dominant form Pathogenic:1
- -
Cardiovascular phenotype Uncertain:1
The p.G1030D variant (also known as c.3089G>A), located in coding exon 46 of the COL1A2 gene, results from a G to A substitution at nucleotide position 3089. The glycine at codon 1030 is replaced by aspartic acid, an amino acid with similar properties. The majority of pathogenic mutations identified to date in COL1A2 have involved the substitution of another amino acid for glycine within the triple-helical domain (Dagleish R. Nucleic Acids Res. 1997 Jan 1;25(1):181-7; Marini JC et al. Hum Mutat. 2007 Mar;28(3):209-21; Bardai G et al. Osteoporos Int 2016 Dec;27(12):3607-3613). An alternate amino acid substitution at this position, p.G1030A, was detected in a reportedly de novo osteogenesis imperfecta type III case (Lindahl K et al. Eur. J. Hum. Genet., 2015 Aug;23:1042-50; Malmgren B et al. Oral Dis, 2017 Jan;23:42-49; Andersson K et al. PLoS ONE, 2017 May;12:e0176466). Internal structural analysis indicates that this alteration disrupts the characteristic G-X-Y motif in the COL1A2 protein and inserts a bulky side chain into a sterically-constrained region (Bella J et al. Science. 1994;266:75-81; Hohenester E et al. Proc. Natl. Acad. Sci. U.S.A. 2008;105:18273-7; Ambry internal data). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at